Inhibrx Biosciences (INBX) Share-based Compensation (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Share-based Compensation data on file, last reported at $2.7 million in Q4 2025.

• Share-based Compensation for Q4 2025 came in at $2.7 million, down 8.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.0 million (down 85.67% YoY), and the FY2025 annual result was $11.1 million, down 80.97% from the prior year.
• Share-based Compensation eased to $2.7 million in Q4 2025 per INBX's latest filing, from $2.8 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $46.2 million in Q2 2024 and troughed at $2.4 million in Q1 2025.
• A 3-year average of $9.6 million and a median of $4.7 million in 2024 frame the typical range for Share-based Compensation.
• On a YoY basis, Share-based Compensation climbed as much as 8.01% in 2025 and fell as far as 94.0% in 2025.
• A 3-year view of Share-based Compensation shows it stood at $6.4 million in 2023, then tumbled by 53.6% to $3.0 million in 2024, then fell by 8.01% to $2.7 million in 2025.
• Business Quant data shows INBX's Share-based Compensation at $2.7 million in Q4 2025, $2.8 million in Q2 2025, and $2.4 million in Q1 2025.